Navigation Links
Cardica Receives NASDAQ Notification of Non-Compliance
Date:9/4/2009

REDWOOD CITY, Calif., Sept. 4 /PRNewswire-FirstCall/ -- Cardica, Inc. (Nasdaq: CRDC) today announced that, on September 2, 2009, it received a notice from the Listing Qualifications Department of The NASDAQ Global Market (NASDAQ) stating that the Company's stock will be delisted from NASDAQ based upon NASDAQ staff's determination that Cardica has not regained compliance with the minimum $10 million stockholders' equity requirement for continued listing on the NASDAQ as stated under NASDAQ Marketplace Rule 5450(b)(1)(A). As a result, Cardica's securities will be delisted from NASDAQ unless, by September 9, 2009, Cardica requests a hearing before a NASDAQ Listing Qualifications Panel (Panel) to appeal the staff's determination. Cardica has requested a hearing before the Panel, and Cardica's securities will remain listed on NASDAQ pending a decision by the Panel following the hearing.

About Cardica

Cardica is a leading provider of automated anastomosis systems for coronary artery bypass graft (CABG) surgery. By replacing hand-sewn sutures with easy-to-use automated systems, Cardica's products provide cardiovascular surgeons with rapid, reliable and consistently reproducible anastomoses, or connections of blood vessels, often considered the most critical aspect of the CABG procedure. Cardica's C-Port(R) Distal Anastomosis Systems are marketed in the United States and Europe and its PAS-Port(R) Proximal Anastomosis System is marketed in the United States, Europe and Japan. In addition, the company has developed the Cardica Microcutter, a true multi-fire endoscopic stapling device designed to be used in a variety of settings including bariatric, thoracic and general surgery.

Forward-Looking Statements

This press release contains "forward-looking statements," including, without limitation, statements related to the continued listing of Cardica's common stock on The NASDAQ Global Market and potential outcomes following the appeal process. The word "will" and similar expressions are intended to identify forward-looking statements. There are a number of important factors that could cause Cardica's results to differ materially from those indicated by these forward-looking statements, including, without limitation, the risk that the Panel may not overturn the staff's determination that Cardica has failed to meet the minimum continued listing requirements and the risk that Cardica otherwise fails to comply with the continued listing requirements of The NASDAQ Global Market or any other NASDAQ market, as well as other risks detailed from time to time in Cardica's SEC reports, including its Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2009. Cardica expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in the company's expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based. You are encouraged to read Cardica's reports filed with the U.S. Securities and Exchange Commission, available at www.sec.gov.


'/>"/>
SOURCE Cardica, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Cardicas C-Port(R) Flex A Anastomosis System Allows Surgeons to Perform Revolutionary Closed-Chest Heart Bypass Surgeries
2. Cardica Receives European CE Mark for C-Port Flex A System for Use in Coronary Artery Bypass Surgery
3. Cardica and Cook Sign Agreement to Expand Cook Vascular Closure Device Product Family
4. Cardica and Intuitive Surgical to Host Educational Symposium on Advanced Techniques and Technologies in Robotic Coronary Revascularization and Mitral Valve Repair
5. Cardica Announces Fiscal 2008 Second Quarter Financial Results and Business Progress
6. Cardica to Present at Jefferies 2nd Annual Healthcare Conference
7. Cardica Receives $1 Million Milestone Payment From Cook Medical for Development of Heart Defect Closure Device
8. Cardica Announces Fiscal 2009 First Quarter Financial Results
9. Cardica Announces Fiscal 2009 Second Quarter Financial Results
10. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
11. Ciphergen Biosystems Receives Noncompliance Letter From The Nasdaq Stock Market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... ... ... Information Management Services ( IMS ) is pleased to announce a major upgrade ... and is so significant it was endowed with a new name, BSI Engage. ... a streamlined layout and a more intuitive format for navigating the system. ...
(Date:2/8/2016)... -- Diplomat Pharmacy, Inc. (NYSE: DPLO) announced today that its new website has gone live. On Thursday, ... mobile-friendly. Visit the new site: www.diplomat.is ... ... ... "The goal was to reimagine the website and create ...
(Date:2/5/2016)...  In the pharmaceutical industry the medical affairs function ... activities including the identification and engagement of key thought ... high in the oncology therapeutic area where most treating ... Role of Medical Affairs in Oncology Launch Excellence ." ... find better ways to utilize medical affairs to develop ...
(Date:2/4/2016)... 4, 2016 - New FDA action date of ... New FDA action date of July 22, 2016   ... 22, 2016   - Lifitegrast ... decade indicated for the treatment of signs and symptoms of dry ... the potential to be the only product approved in the U.S. in the past decade ...
Breaking Biology Technology:
(Date:2/3/2016)... PUNE, India , February 3, 2016 ... to the new market research report "Automated Fingerprint Identification ... (Tenprint Search, Latent Search), Application (Banking & Finance, Government, ... 2020", published by MarketsandMarkets, the market is expected to ... estimated CAGR of 21.0% between 2015 and 2020. The ...
(Date:2/3/2016)... 3, 2016 ... the "Emotion Detection and Recognition Market ... Others), Software Tools (Facial Expression, Voice Recognition ... Regions - Global forecast to 2020" ... http://www.researchandmarkets.com/research/d8zjcd/emotion_detection ) has announced the addition ...
(Date:2/2/2016)... This BCC Research report provides a ... the recent advances in high throughput ‘omic platforms ... forward. Includes forecast through 2019. Use ... opportunities that exist in the bioinformatic market. Analyze ... well as IT and bioinformatics service providers. Analyze ...
Breaking Biology News(10 mins):